Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MVRBF's Cash-to-Debt is ranked higher than
88% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. MVRBF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MVRBF' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.85
MVRBF's Equity-to-Asset is ranked higher than
75% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MVRBF: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
MVRBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.75  Med: 0.86 Max: 0.92
Current: 0.85
0.75
0.92
Piotroski F-Score: 5
Altman Z-Score: 6.29
Beneish M-Score: -2.34
WACC vs ROIC
6.93%
-140.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -996.51
MVRBF's Operating Margin % is ranked lower than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. MVRBF: -996.51 )
Ranked among companies with meaningful Operating Margin % only.
MVRBF' s Operating Margin % Range Over the Past 10 Years
Min: -996.51  Med: -14.72 Max: 67.27
Current: -996.51
-996.51
67.27
Net Margin % 664.99
MVRBF's Net Margin % is ranked higher than
99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. MVRBF: 664.99 )
Ranked among companies with meaningful Net Margin % only.
MVRBF' s Net Margin % Range Over the Past 10 Years
Min: -527.08  Med: -8.18 Max: 664.99
Current: 664.99
-527.08
664.99
ROE % 17.99
MVRBF's ROE % is ranked higher than
93% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. MVRBF: 17.99 )
Ranked among companies with meaningful ROE % only.
MVRBF' s ROE % Range Over the Past 10 Years
Min: -35.27  Med: 0.95 Max: 79.91
Current: 17.99
-35.27
79.91
ROA % 16.11
MVRBF's ROA % is ranked higher than
95% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. MVRBF: 16.11 )
Ranked among companies with meaningful ROA % only.
MVRBF' s ROA % Range Over the Past 10 Years
Min: -46.95  Med: -4.96 Max: 71.26
Current: 16.11
-46.95
71.26
ROC (Joel Greenblatt) % -1420.22
MVRBF's ROC (Joel Greenblatt) % is ranked lower than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. MVRBF: -1420.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MVRBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1420.22  Med: -18.65 Max: 1014.95
Current: -1420.22
-1420.22
1014.95
3-Year Revenue Growth Rate -37.70
MVRBF's 3-Year Revenue Growth Rate is ranked lower than
82% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MVRBF: -37.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MVRBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -45.4  Med: -9.7 Max: 85.9
Current: -37.7
-45.4
85.9
GuruFocus has detected 1 Warning Sign with Medivir AB $MVRBF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MVRBF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MVRBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:OSTO:ATORX, OSTO:WTX, OSTO:BINV, OSTO:ISOFOL, OSTO:IMMU, OSTO:VICO, OSTO:ONCO, OSTO:IBT B, OSTO:ACTI, NGM:MERT MTF A, XSAT:DEX, OSTO:KAN, XSAT:WNT, OSTO:ENZY, OSTO:KDEV, XSAT:EUCI, OSTO:BIOVIC B, OSTO:CANTA, NGM:GTAB B, OSTO:GENO » details
Traded in other countries:MVR.Germany, MVIR B.Sweden, 0GP7.UK,
Headquarter Location:Sweden
Medivir AB is a research based pharmaceutical company. It develops innovative pharmaceuticals for the treatment of cancer. The company specialises in research into protease inhibitors and in the science of nucleotides and nucleosides.

Medivir AB is a pharmaceutical company with an R&D focus on infectious diseases and hepatitis C. The Company works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Its research focuses on infectious diseases and has expertise in the chemistry and biology of the enzyme classes, polymerase and protease. The research portfolio comprises nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by the Company and Janssen. Positive simeprevir phase III data was reported in December 2012 that will, together with previous phase II data, form the basis for registration applications in the USA, Europe and Japan. The Company markets pharmaceuticals in the Nordic market. The product range comprises approximately 16 prescription pharmaceuticals in different therapeutic spheres. The products include Citodon, Laxabon,Lithionit, Mollipect and Paraflex. Parallel imports of pharmaceuticals to the Swedish market are conducted via the wholly owned subsidiary company, Cross Pharma.

Top Ranked Articles about Medivir AB

Medivir Appoints John Öhd as Chief Medical Officer
Medivir's CFO Will Leave his Position - Successor Recruitment Underway
Resolutions at the Annual General Meeting in Medivir on 3 May 2017
Update on the Development of Simeprevir as Part of the Triple Combination With AL-335 and Odalasvir (JNJ-4178)
Medivir - New data for Simeprevir Will be Presented at EASL's International Liver Congress™ 2017
Medivir - New Data on MIV-818 Will be Presented at EASL's International Liver Congress™ 2017
Annual Report 2016 - Medivir
Notice of Annual General Meeting of Medivir AB (publ)
Number of Shares and Votes in Medivir
Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy The goal is to investigate the treatment's efficacy, safety and pharmacokinetics
Medivir AB (MVRBF) announced Janssen Research & Development, part of Johnson & Johnson's (NYSE:JNJ) Janssen Pharmaceutical Companies, has commenced a clinical research trial for JNJ-4178, a treatment for individuals with chronic hepatitis C. No placebo will be used for non-cirrhotic patients infected with genotype 1, 2, 4, 5 and 6 of the hepatitis C virus that have taken an anti-HCV therapy in the past. Read more...

Ratios

vs
industry
vs
history
PE Ratio 8.85
MVRBF's PE Ratio is ranked higher than
90% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MVRBF: 8.85 )
Ranked among companies with meaningful PE Ratio only.
MVRBF' s PE Ratio Range Over the Past 10 Years
Min: 2.01  Med: 8.7 Max: 76.94
Current: 8.85
2.01
76.94
Price-to-Owner-Earnings 11.89
MVRBF's Price-to-Owner-Earnings is ranked higher than
78% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. MVRBF: 11.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MVRBF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.21  Med: 6.8 Max: 59.09
Current: 11.89
2.21
59.09
PB Ratio 1.91
MVRBF's PB Ratio is ranked higher than
77% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. MVRBF: 1.91 )
Ranked among companies with meaningful PB Ratio only.
MVRBF' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.04 Max: 14.46
Current: 1.91
0.91
14.46
PS Ratio 9281.25
MVRBF's PS Ratio is ranked lower than
99% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. MVRBF: 9281.25 )
Ranked among companies with meaningful PS Ratio only.
MVRBF' s PS Ratio Range Over the Past 10 Years
Min: 1.34  Med: 6.56 Max: 10375
Current: 9281.25
1.34
10375
EV-to-EBIT -2.27
MVRBF's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. MVRBF: -2.27 )
Ranked among companies with meaningful EV-to-EBIT only.
MVRBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.1  Med: -3.3 Max: 127.8
Current: -2.27
-72.1
127.8
EV-to-EBITDA -2.30
MVRBF's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. MVRBF: -2.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
MVRBF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.1  Med: -3.3 Max: 127.8
Current: -2.3
-72.1
127.8
Current Ratio 5.78
MVRBF's Current Ratio is ranked higher than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. MVRBF: 5.78 )
Ranked among companies with meaningful Current Ratio only.
MVRBF' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.96 Max: 11.67
Current: 5.78
1.84
11.67
Quick Ratio 5.78
MVRBF's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. MVRBF: 5.78 )
Ranked among companies with meaningful Quick Ratio only.
MVRBF' s Quick Ratio Range Over the Past 10 Years
Min: 1.83  Med: 4.79 Max: 11.49
Current: 5.78
1.83
11.49
Days Sales Outstanding 130.43
MVRBF's Days Sales Outstanding is ranked lower than
81% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. MVRBF: 130.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
MVRBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.49  Med: 35.12 Max: 150.16
Current: 130.43
14.49
150.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.90
MVRBF's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. MVRBF: 4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MVRBF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.2  Med: -9.6 Max: 5
Current: 4.9
-15.2
5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.63
MVRBF's Price-to-Net-Cash is ranked higher than
82% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. MVRBF: 2.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MVRBF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.71  Med: 7.57 Max: 34.7
Current: 2.63
1.71
34.7
Price-to-Net-Current-Asset-Value 2.31
MVRBF's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. MVRBF: 2.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MVRBF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.53  Med: 4.97 Max: 16.15
Current: 2.31
1.53
16.15
Price-to-Tangible-Book 2.25
MVRBF's Price-to-Tangible-Book is ranked higher than
77% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MVRBF: 2.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MVRBF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.49  Med: 3.94 Max: 11.21
Current: 2.25
1.49
11.21
Price-to-Intrinsic-Value-Projected-FCF 0.89
MVRBF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. MVRBF: 0.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MVRBF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 0.86 Max: 34.35
Current: 0.89
0.53
34.35
Price-to-Median-PS-Value 930.00
MVRBF's Price-to-Median-PS-Value is ranked lower than
100% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MVRBF: 930.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MVRBF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.04 Max: 1485
Current: 930
0.21
1485
Earnings Yield (Greenblatt) % -44.05
MVRBF's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. MVRBF: -44.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MVRBF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -240.3  Med: -2.8 Max: 644.9
Current: -44.05
-240.3
644.9

More Statistics

Revenue (TTM) (Mil) $5.50
EPS (TTM) $ 0.87
Beta0.28
Short Percentage of Float0.00%
52-Week Range $7.40 - 10.10
Shares Outstanding (Mil)20.31
» More Articles for MVRBF

Headlines

Articles On GuruFocus.com
Medivir Appoints John Öhd as Chief Medical Officer Jun 19 2017 
Medivir's CFO Will Leave his Position - Successor Recruitment Underway May 30 2017 
Resolutions at the Annual General Meeting in Medivir on 3 May 2017 May 03 2017 
Update on the Development of Simeprevir as Part of the Triple Combination With AL-335 and Odalasvir Apr 24 2017 
Medivir - New data for Simeprevir Will be Presented at EASL's International Liver Congress™ 2017 Apr 06 2017 
Medivir - New Data on MIV-818 Will be Presented at EASL's International Liver Congress™ 2017 Apr 06 2017 
Annual Report 2016 - Medivir Apr 04 2017 
Notice of Annual General Meeting of Medivir AB (publ) Apr 03 2017 
Number of Shares and Votes in Medivir Mar 31 2017 
Johnson & Johnson's Janssen Pharmaceutical Starts Study on Hepatitis C Therapy Nov 28 2016 

More From Other Websites
Medivir Appoints John Öhd as Chief Medical Officer Jun 19 2017
Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring... Jun 09 2017
Medivir's CFO Will Leave his Position - Successor Recruitment Underway May 30 2017
Medivir AB :MVRBY-US: Earnings Analysis: 2016 By the Numbers : April 26, 2017 Apr 26 2017
Annual Report 2016 - Medivir Apr 04 2017
Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development Mar 16 2017
Medivir's Nomination Committee Proposes new Board of Directors Ahead of 2017 AGM Feb 24 2017
Executive Management Team Members Increase Their Holdings in Medivir Feb 17 2017
Christine Lind new CEO of Medivir AB Effective 1 April 2017 Feb 09 2017
Medivir Capital Markets Meeting on 23 February 2017 Feb 06 2017
Resolutions at the Extraordinary General Meeting in Medivir on 2 February 2017 Feb 02 2017
Notice of Extraordinary General Meeting of Medivir AB (publ) Jan 10 2017
Medivir - Invitation to Conference Call and Webcast Jan 09 2017
Medivir Completes Previously Announced Oncology Programs Acquisition Dec 29 2016
Medivir Completes the Divestment of BioPhausia - a Transfer of Approx. SEK 870m to the Shareholders... Dec 15 2016
Medivir's fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323,... Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}